|
Post by mnkdfann on Jan 4, 2019 16:10:36 GMT -5
IMO, the conference call was about as good as could be expected.
What would concern me, if I was a worrier (or owned more than the handful of shares I do), would be the financial and approval forecasts. Last year's financial and approval forecasts were IMO pretty bad. Will they really be better this time?
|
|
|
Post by mnkdfann on Jan 4, 2019 13:47:49 GMT -5
Yep, bought it on the Thursday you mentioned it, @ $1.79, then ((((((((BOOM!!!!))))))))) havent hit one like that since. Many Thanks brother ✌🏻😎 I once was looking at Vermillion when it was .04..supposed to go bankrupt thee next day..but then that night the FDA approved their medical device..and it went over $30..that was 1 device..but it happened to be the only FDA approved Ovarian cancer test in the U.S....I will take a look around...and do some datamining.. True, but just to clarify it did not go from 0.04 to over $30 over night (not that you said it did, but some could have read it that way). It took some months. And with hindsight, it was a speculative bubble. Trading today at 0.40. With a market cap below that of MNKD's. But if your data mining reveals some good picks please do post them for us in the Other Stocks area.
|
|
|
Post by mnkdfann on Jan 3, 2019 21:27:51 GMT -5
Maybe I missed it but did he explain exactly what the "AFAL protocol" consists of? I believe its "afrezza first afrezza last" as opposed to the "Treat to Fail" Four Step ADA protocol From the white paper: "We described that new paradigm as “Afrezza First, Afrezza Instead, Afrezza Always,” more easily referred to as “AFAL” (people in diabetes love to try to come up with clever acronyms). Consequently, Vdex developed its own proprietary AFAL protocols." The actual protocols are alluded to on the next pages, but not explicitly spelled out in detail AFAIK (e.g. dosing is said to be aggresive, but details are missing). Respectfully, the white paper style is a little sloppy and inconsistent. E.g., at times it says AFAL protocol (singular) and elsewhere AFAL protocols (plural). Assuming the AFAL protocols are proprietary, it makes perfect sense they are not stated in detail.
|
|
|
Post by mnkdfann on Jan 3, 2019 17:20:50 GMT -5
Nope he was talking about his MNKD shares, he’s been in since the beginning. Very large shareholder! In that case, WOW!
|
|
|
Post by mnkdfann on Jan 3, 2019 17:07:13 GMT -5
Down 98% Considers it a loss? Does that mean that he sold those shares? If not and he still has those shares ... then today's share price of $1.14 is his 2%. Which means that his original cost is $1.14/.02 = $57 per share. Wow! No wonder he's pissed ! I assumed he was talking about the loss he's taken starting up and running Vdex clinics. Not on MNKD shares per se. A huge proportion of new small businesses fail, so it is not entirely surprising if his business model was (at least to date) suffering.
|
|
|
Post by mnkdfann on Jan 2, 2019 17:37:33 GMT -5
Thanks aged, but how do those amounts square with the statement that the remaining liability is only $8.8 mil? As I read it, the Milestone Rights liability is an estimated fair value of future milestone obligations / payments. That suggests to me that the 10s of millions of milestone payments are considered to be unlikely to ever be paid, or will be paid so far in the future that they are being massively discounted. I'll go with the latter unless someone has a better explanation.
|
|
|
Post by mnkdfann on Jan 1, 2019 9:37:12 GMT -5
If he is able to turn MNKD into the growth company and get it back to its $55pps is he being paid enough? While we would all like to see things move faster they are moving in the right direction. Today, the lights are still on and the open for business sign is on the door. One year ago many bet this would not be the case.
Seriously, I doubt that many if any made such an all or nothing bet. More than likely they invested (buying puts, shorting, etc.) in such a way that they would profit if the SP went down. And they won that bet. Happy New Year, and GLTATL in 2019.
|
|
|
Post by mnkdfann on Jan 1, 2019 9:33:54 GMT -5
They are seriously overpaying the CTO. Time will tell. 2019 will be the year of reckoning.
If he is able to turn MNKD into the growth company and get it back to its $55pps is he being paid enough?
You think the CTO (technology officer) will do that?
|
|
|
Post by mnkdfann on Dec 31, 2018 22:23:47 GMT -5
Matt also said: "A firm can either pay the going rate for a CEO, CFO, or medical director or they can expect to have their executives hired away by a competitor willing to pay more. If MNKD wants competent executives, they have to pay the market rate or do with inferior talent." While the reported compensation figures may be inflated (and potentially misleading), they may be inflated a lot or only a little for any particular individual. IOTW, if these Mannkind executives are as good as many insist they are, I doubt they are being paid chicken-feed.
|
|
|
Post by mnkdfann on Dec 31, 2018 13:57:58 GMT -5
The companies cash runway was already much improved and Afrezza sales are climbing albeit slowly. Why have an investor conference call on Friday unless there's something more significant to report than mundane details about the recent stock sale? There is no reason for a conference call just to rehash updates on finances and the many other things already known. There was practically a small shareholder revolt calling for details, which is why I thought the call was called.
|
|
|
Post by mnkdfann on Dec 31, 2018 11:51:06 GMT -5
Also thinking differently, a small RLS card has been played but I think the big RLS card is still in Mike's hand. I've always thought that Andrea Leones-Bay leaving MannKind to work for Receptor was a big clue to Receptor's future. Why would she leave her years of work developing Technosphere for a brand new startup? Andrea is now developing cannabis-based pharmaceuticals and she continues to utilize the Technosphere delivery platform. I've often wondered whether MannKind is planning some future M&A action with Receptor. Cannabis stock is hot and, since precision pharmaceutical-grade cannabis drugs with FDA approval are virtually non-existent, Receptor's API family has the potential be quite lucrative. Arguably, it's the precision dosing of TS that makes any RLS TS-drug more likely to gain medical acceptance than the "hit or miss" (pun intended) profile of oral, liquid and even larger-molecule pulmonary carriers. In an old FAQ, Mannkind insisted her move to RLS was her own, in no way coordinated by Mannkind, etc. I suppose they could have been stupidly and unwisely misleading investors, but I would hope not. www.mannkindcorp.com/Collateral/Documents/English-US/MNKD%202%203%2016%20Investor%20Call%20FAQ%20v2%209%2016%20FINAL.pdf
|
|
|
Post by mnkdfann on Dec 30, 2018 9:00:28 GMT -5
The call starts at 9 a.m. on Friday. I'm thinking they aren't going to talk for long, or they would have started the call earlier so as not to run past the market opening bell at 9:30 a.m. Of course, they can halt shares of MNKD past 9:30 if the call goes on past that, but I think (I could be wrong) they are probably hoping to wrap it up before then. If it was going to be a longer in-depth call, why not just start at 8:30 a.m.?
If I am correct, it suggests they are not planning to take many if any questions.
|
|
|
Post by mnkdfann on Dec 29, 2018 15:58:37 GMT -5
how many shares do they have left to work with after this last offering? Anyone know? Issued vs Authorized? answered my own question. 186M outstanding, 280M authorized, 94M remaining. IDK, but IIRC, I've seen various people post that the available shares are significantly fewer than that. Are you remembering to reduce the count to adjust for warrants?
|
|
|
Post by mnkdfann on Dec 28, 2018 15:14:37 GMT -5
Mannkind top owners now are experts in shorting and bk companies
FLYNN JAMES E has 14,576,376 shares CVI INVESTMENTS, INC. has 11,750,000 shares
And consider / tie in my observation on page 2 of this thread: mnkd.proboards.com/thread/10675/new-board-member-christine-mundkur?page=2It may not mean anything, but it is perhaps a little weird who is being recruited to the team.
|
|
|
Post by mnkdfann on Dec 28, 2018 12:50:08 GMT -5
What price did they buy in at? Sorry if it is obvious but I don't see that info anywhere just now (tiny cell screen).
|
|